From: Prevalence of clinically actionable disease variants in exceptionally long-lived families
SNP ID* | Gene | Amino Acid Change | Random LLFS Sampling Frequency | Population Frequency | p-value | ACMG Variant Classification: Criteria* | Number of LLFS Participants with Variant |
---|---|---|---|---|---|---|---|
rs28897686: NM_007294.3:c.3748G > T | BRCA1 | p.Glu1250* | 2.57 × 10−4 | 7.90 × 10−6 | 1 | P: PVS1, PM2, PP5 | 3 heterozygotes |
rs764575966: NM_003001.3:c.397C > T | SDHC | p.Arg133* | 7.71 × 10−4 | 3.20 × 10−5 | 0.05 | P: PVS1, PM2, PP5 | 3 heterozygotes |
rs74315294: NM_000098.3:c.338C > T | CPT2 | p.Ser113Leu | 3.96 × 10−3 | 1.38 × 10− 3 | 0.11 | P: PM1, PM2, PP3, PP5 | 391 heterozygotes 3 homozygotes |
rs121434280: NM_001127328.2:c.211 T > C | ACADM | p.Tyr71His | 2.06 × 10−4 | 4.87 × 10− 4 | 1 | LP: PS3, PM2, PP5, BP4 | 136 heterozygotes |
rs201375579: NM_001127328.2:c.809A > G | ACADM | p.Asp270Gly | 4.30 × 10−5 | 2.97 × 10−4 | 1 | LP: PS3, PM2 | 79 heterozygotes |
rs138058572: NM_001270447.1:c.1427G > A | ACADVL | p.Arg476Gln | 2.98 × 10−4 | 7.20 × 10−6 | N/A | LP: PS4, PM2, PP3 | 1 heterozygote |
rs28904921: NM_000051.3:c.7271 T > G | ATM | p.Val2424Gly | 2.20 × 10−5 | 5.06 × 10− 5 | 1 | LP: PS3, PM2,PP3,PP5 | 14 heterozygotes |
rs137852849: NM_001164675.1:c.836C > T | SUMF1 | p.Ala279Val | 2.24 × 10−4 | 1.12 × 10− 4 | 1 | LP: PS3, PM2,PP5 | 31 heterozygotes |
rs17847577: NM_000553.4:c.1105C > T | WRN | p.Arg369* | 1.73 × 10−4 | 1.88 × 10− 4 | 1 | P: PVS1, PM2, PP5 | 53 heterozygotes |